Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Research & Development (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Research & Development readings, the most recent being $27.5 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 61.62% to $27.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $105.0 million, a 2.65% increase, with the full-year FY2025 number at $96.9 million, down 13.23% from a year prior.
  • Research & Development hit $27.5 million in Q1 2026 for Kiniksa Pharmaceuticals International, down from $34.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $35.2 million in Q4 2024 to a low of $13.8 million in Q2 2022.
  • Median Research & Development over the past 5 years was $20.8 million (2022), compared with a mean of $22.1 million.
  • Biggest five-year swings in Research & Development: tumbled 47.54% in 2022 and later soared 75.62% in 2024.
  • Kiniksa Pharmaceuticals International's Research & Development stood at $14.4 million in 2022, then surged by 39.35% to $20.1 million in 2023, then skyrocketed by 75.62% to $35.2 million in 2024, then decreased by 1.72% to $34.6 million in 2025, then decreased by 20.61% to $27.5 million in 2026.
  • The last three reported values for Research & Development were $27.5 million (Q1 2026), $34.6 million (Q4 2025), and $24.2 million (Q3 2025) per Business Quant data.